EMPAVELI
safety profile
This safety profile is from the PEGASUS study
Alert
Serious adverse reactions were reported in 17% of patients treated with EMPAVELI1
  • The most common serious adverse reaction was infections (5%)1
The most common ARs (≥10%) with EMPAVELI vs eculizumab, respectively, in PEGASUS study1
  • Injection-site reactions: 39% vs 5%
    • Injection-site reactions were mild or moderate in severity, with none leading to study discontinuation1,2
  • Infections: 29% vs 26%
  • Diarrhea: 22% vs 3%
    • All diarrhea cases were mild and did not lead to study discontinuation3
  • Abdominal pain: 20% vs 10%
  • Respiratory tract infection: 15% vs 13%
  • Viral Infection: 12% vs 8%
  • Fatigue: 12% vs 23%
Clinically relevant adverse reactions in less than 5% of patients include1:
  • Intestinal ischemia
  • Biliary sepsis
  • Hypersensitivity pneumonitis
Image is an actor portrayal.
Adverse reactions reported in ≥5% of patients treated with EMPAVELI1
Adverse reactions
EMPAVELI
(n=41)
n (%)
eculizumab
(n=39)
n (%)
General disorders and administration-site conditions
Injection-site reaction* 16 (39) 2 (5)
Fatigue* 5 (12) 9 (23)
Chest pain* 3 (7) 1 (3)
Infections and infestations
Infections* 12 (29) 10 (26)
Respiratory tract infection* 6 (15) 5 (13)
Viral Infection* 5 (12) 3 (8)
Gastrointestinal disorders
Diarrhea 9 (22) 1 (3)
Abdominal pain* 8 (20) 4 (10)
Musculoskeletal disorders
Back pain* 3 (7) 4 (10)
Nervous system disorders
Headache 3 (7) 9 (23)
Vascular disorders
Systemic hypertension* 3 (7) 1 (3)
*The following terms were combined:
Abdominal pain
includes: abdominal pain upper, abdominal discomfort, abdominal pain, abdominal pain lower, abdominal tenderness, epigastric discomfort;
Back pain
includes: back pain, sciatica;
Chest pain
includes: chest discomfort, non-cardiac chest pain, musculoskeletal chest pain, chest pain;
Fatigue
includes: asthenia, lethargy, fatigue;
Infections
include: oral herpes, bacterial infection, fungal infection, gastrointestinal infection, gastrointestinal viral infection, influenza-like illness, nasopharyngitis, pulpitis dental, rhinitis, tonsillitis, tonsillitis bacterial, vulvovaginal mycotic infection, hordeolum, sepsis, furuncle, otitis externa, viral respiratory tract infection, gastroenteritis, upper respiratory tract infection, bronchitis, ear infection, respiratory tract infection, rhinovirus infection, sinusitis, urinary tract infection;
Injection-site reaction
includes: injection-site erythema, injection-site reaction, injection-site swelling, injection-site induration, injection-site bruising, injection-site pain, injection-site pruritus, vaccination-site reaction, administration-site swelling, injection-site hemorrhage, injection-site edema, injection-site warmth, administration-site pain, application-site pain, injection-site mass, injection-site rash, vaccination-site pain;
Respiratory tract infection
includes: influenza-like illness, nasopharyngitis, rhinitis, tonsillitis, viral upper respiratory tract infection, upper respiratory tract infection, respiratory tract infection, sinusitis;
Systemic hypertension
includes: hypertension;
Viral infection
includes: oral herpes, gastrointestinal viral infection, viral upper respiratory tract infection, rhinovirus infection.1
REMS Program Information
VACCINATION REQUIREMENTS
The Risk Evaluation and Mitigation Strategy (REMS) program for EMPAVELI1
Because of the risk of serious infections, EMPAVELI is available only through a restricted program under a REMS. Under the EMPAVELI REMS, prescribers must enroll in the program.
Prescribers must counsel patients about the risk of serious infection, provide patients with REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria.
Enrollment in the EMPAVELI REMS and additional information are available by telephone: 1‑888‑343-7073 or at www.empavelirems.com.
Prescribers must enroll in the REMS program before writing a prescription for EMPAVELI. Prescribers will only need to register once.
What to know before prescribing EMPAVELI to your patients1
Vaccinate patients against encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B at least 2 weeks prior to initiation of EMPAVELI therapy according to current Advisory Committee on Immunization Practices (ACIP) guidelines.
Provide 2 weeks of antibacterial drug prophylaxis to patients if EMPAVELI must be initiated immediately and vaccines are administered less than 2 weeks before starting therapy with EMPAVELI.
Healthcare professionals who prescribe EMPAVELI must enroll in the REMS for EMPAVELI.
Essential guidance
for patient dosing and
administration
Learn more
Image is an actor portrayal.
AR=adverse reaction; LDH=lactate dehydrogenase; ULN=upper limit of normal.

References: 1. EMPAVELI [prescribing information]. Waltham, MA: Apellis Pharmaceuticals, Inc.; 2021. 2. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384:1028-1037. 3. Data on file. Apellis Pharmaceuticals, Inc., Waltham, MA.

Indication and Important Safety Information

INDICATION

EMPAVELI™ (pegcetacoplan) is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

IMPORTANT SAFETY INFORMATION

EMPAVELI™ (pegcetacoplan) is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA Meningococcal infections may occur in patients treated with EMPAVELI and may become rapidly life-threatening or fatal if not recognized and treated early. Use of EMPAVELI may predispose individuals to serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B.

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria.
  • Vaccinate patients at least 2 weeks prior to administering the first dose of EMPAVELI unless the risks of delaying therapy with EMPAVELI outweigh the risk of developing a serious infection.
  • Vaccination reduces, but does not eliminate, the risk of serious infections. Monitor patients for early signs of serious infections and evaluate immediately if infection is suspected.

EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the EMPAVELI REMS, prescribers must enroll in the program.

CONTRAINDICATIONS

  • Hypersensitivity to pegcetacoplan or to any of the excipients
  • Not currently vaccinated against certain encapsulated bacteria, unless the risks of delaying EMPAVELI treatment outweigh the risks of developing a bacterial infection with an encapsulated organism
  • Unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae

WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

The use of EMPAVELI may predispose individuals to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B (Hib). To reduce the risk of infection, all patients must be vaccinated against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI.

For patients without known history of vaccination, administer required vaccines at least 2 weeks prior to receiving the first dose of EMPAVELI. If immediate therapy with EMPAVELI is indicated, administer required vaccine as soon as possible and provide patients with 2 weeks of antibacterial drug prophylaxis.

Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider discontinuation of EMPAVELI in patients who are undergoing treatment for serious infections.

EMPAVELI REMS

Because of the risk of serious infections, EMPAVELI is available only through a restricted program under a REMS. Under the EMPAVELI REMS, prescribers must enroll in the program and must counsel patients about the risk of serious infection, provide the patients with the REMS educational materials, and ensure patients are vaccinated against encapsulated bacteria. Enrollment and additional information are available by telephone: 1-888-343-7073 or at www.empavelirems.com.

Infusion-Related Reactions

Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria) have occurred in patients treated with EMPAVELI. One patient (less than 1% in clinical studies) experienced a serious allergic reaction which resolved after treatment with antihistamines. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.

Monitoring PNH Manifestations after Discontinuation of EMPAVELI

After discontinuing treatment with EMPAVELI, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues EMPAVELI for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI.

Interference with Laboratory Tests

There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥10% of patients) with EMPAVELI vs. eculizumab were injection-site reactions (39% v. 5%), infections (29% v. 26%), diarrhea (22% v. 3%), abdominal pain (20% v. 10%), respiratory tract infection (15% v. 13%), viral infection (12% v. 8%), and fatigue (12% v. 23%).

USE IN SPECIFIC POPULATIONS

Females of Reproductive Potential

EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.

Please see full Prescribing Information, including Boxed WARNING regarding serious infections caused by encapsulated bacteria, and Medication Guide.